Platform · Observational Protocol Library

Every protocol starts with a clinical question and defines the episode of care that answers it.

Other platforms answer which medical code maximizes reimbursement. Circles Datasets answer which diagnostic method, treatment protocol, medical product, and pre- and post-intervention therapy work best for a specific patient cohort, followed from baseline to long-term outcome. Each answer begins with a fit-for-purpose protocol.

Protocols in the library78
Anatomical region
Condition
Treatment
Outcome measure
Showing
78
of
78
Circles
Reset filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
M16.0-20999-P77
Physicians-Owned Circle

Bilateral Hips / Osteoarthritis / MFAT / VAS + HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS; HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Hip Osteoarthritis.

View Circle detail →
MFAT
MFAT
M16.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Hip Osteoarthritis.

In terms of prevalence, hip osteoarthritis is the third most common of adult men and women. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M16.0-20999-P76
Physicians-Owned Circle

Hip / Osteoarthritis / MFAT / VAS + HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS; HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Hip Osteoarthritis.

View Circle detail →
MFAT
MFAT
M16.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Hip Osteoarthritis.

In terms of prevalence, hip osteoarthritis is the third most common of adult men and women. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M17.0-20999-P75
Physicians-Owned Circle

Bilateral Knees / Osteoarthritis / MFAT / VAS + KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS; KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Knee Osteoarthritis.

View Circle detail →
MFAT
MFAT
M17.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Knee Osteoarthritis.

The Regenerative Medicine Market is valued at 32.5 USD Billion in 2023, and is estimated to grow to over 235.98 USD Billion by 2032. Osteoarthritis of the knee remains one of the most prevalent indications of adult men and women, and is treated area for MFAT therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Knee Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M17.0-20999-P74
Physicians-Owned Circle

Knee / Osteoarthritis / MFAT / VAS + KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS; KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Knee Osteoarthritis.

View Circle detail →
MFAT
MFAT
M17.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of MFAT for Knee Osteoarthritis.

The Regenerative Medicine Market is valued at 32.5 USD Billion in 2023, and is estimated to grow to over 235.98 USD Billion by 2032. Osteoarthritis of the knee remains one of the most prevalent indications of adult men and women, and is treated area for MFAT therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Knee Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M19.019-20999-P73
Physicians-Owned Circle

Bilateral Shoulders / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + QuickDASH

Shoulder
 ·
Osteoarthritis
 ·
VAS; QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of orthobiologics treatments (PRP, BMAC, SVF and MFAT).

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M19.019
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of orthobiologics treatments (PRP, BMAC, SVF and MFAT) for Shoulder Osteoarthritis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Osteoarthritis cases, outcomes and other case data.

M19.019-20999-P72
Physicians-Owned Circle

Shoulder / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + QuickDASH

Shoulder
 ·
Osteoarthritis
 ·
VAS; QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of orthobiologics treatments (PRP, BMAC, SVF and MFAT).

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M19.019
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of orthobiologics treatments (PRP, BMAC, SVF and MFAT) for Shoulder Osteoarthritis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Osteoarthritis cases, outcomes and other case data.

M16.0-20999-P71
Physicians-Owned Circle

Bilateral Hips / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS + HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Hip Osteoarthritis.

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M16.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Hip Osteoarthritis.

Osteoarthritis of the hip remains one of the most prevalent indications of adult men and women, and is a treated area for Regenerative Therapies such as PRP, BMAC, MFAT, and SVF. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip Osteoarthritis cases, outcomes and other case data.

M16.0-20999-P70
Physicians-Owned Circle

Hip / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS; HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Hip Osteoarthritis.

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M16.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Hip Osteoarthritis.

Osteoarthritis of the hip remains one of the most prevalent indications of adult men and women, and is a treated area for Regenerative Therapies such as PRP, BMAC, MFAT, and SVF. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip Osteoarthritis cases, outcomes and other case data.

M17.0-20999-P69
Physicians-Owned Circle

Bilateral Knees / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS; KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Knee Osteoarthritis.

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M17.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Knee Osteoarthritis.

Osteoarthritis of the knee remains one of the most prevalent indications of adult men and women, and is a treated area for Regenerative Therapies such as PRP, BMAC, MFAT, and SVF. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Knee Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M17.0-20999-P68
Physicians-Owned Circle

Knee / Osteoarthritis / PRP + BMAC + MFAT + SVF / VAS + KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS; KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Knee Osteoarthritis.

View Circle detail →
PRP + BMAC + MFAT + SVF
PRP + BMAC + MFAT + SVF
M17.0
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Regenerative Therapies for Knee Osteoarthritis.

Osteoarthritis of the knee remains one of the most prevalent indications of adult men and women, and is a treated area for Regenerative Therapies such as PRP, BMAC, MFAT, and SVF. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Knee Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

B07.0-17110-P67
Physicians-Owned Circle

Foot and Ankle / Fungal Nails and Warts / Class IV Lasers / VAS + SF-12

Foot, Ankle
 ·
Fungal Nails and Warts
 ·
VAS; SF-12

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Fungal Nails/Warts.

View Circle detail →
Class IV Lasers
Class IV Lasers
B07.0
17110

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Fungal Nails/Warts.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Fungal Nails/Warts of adult men and women can be treated with Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Fungal Nails/Warts. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Fungal Nails/Warts cases, outcomes and other case data.

M19.079-97039-P66
Physicians-Owned Circle

Foot and Ankle / Osteoarthritis / Class IV Laser / VAS + FFI

Foot, Ankle
 ·
Osteoarthritis
 ·
VAS; FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Foot Osteoarthritis.

View Circle detail →
Class IV Laser
Class IV Laser
M19.079
97039

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Foot Osteoarthritis.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. The prevalence of Foot Osteoarthritis is approximately 20-30% of people aged 50 and older. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Foot Osteoarthritis cases, outcomes and other case data.

S93.409A-97039-P65
Physicians-Owned Circle

Foot and Ankle / Ankle Sprains and Fractures / Class IV Lasers / VAS + FFI

Foot, Ankle
 ·
Ankle Sprains and Fractures
 ·
VAS; FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Ankle Sprains/Fractures.

View Circle detail →
Class IV Lasers
Class IV Lasers
S93.409A
97039

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Ankle Sprains/Fractures.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Ankle Sprains/Fractures of adult men and women is treated area for Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Ankle Sprains/Fractures. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Ankle Sprains/Fractures cases, outcomes and other case data.

M25.56-97039-P64
Physicians-Owned Circle

Knee / Common Knee Injuries / Class IV Laser / VAS + KOOS

Knee
 ·
Common Knee Injuries
 ·
VAS; KOOS

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Common Knee Injuries.

View Circle detail →
Class IV Laser
Class IV Laser
M25.56
97039

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Common Knee Injuries.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing laser products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Common Knee Injury cases, outcomes and other case data.

M72.2-20999-P63
Physicians-Owned Circle

Foot and Ankle / Plantar Fasciitis / Shockwave / VAS + FFI - Bilateral

Foot, Ankle
 ·
Plantar Fasciitis
 ·
VAS + FFI - Bilateral

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Plantar Fasciitis.

View Circle detail →
Shockwave
Shockwave
M72.2
20999

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Plantar Fasciitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. The prevalence of Plantar Fasciitis is around 10% of the population, with peak incidence in people aged 40 to 60. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Plantar Fasciitis cases, outcomes and other case data.

G56.03-0232T-P62
Physicians-Owned Circle

Hand and Wrist / Carpal Tunnel Syndrome (CTS) / PRP / VAS + QuickDASH

Hand, Wrist
 ·
Carpal Tunnel Syndrome (CTS)
 ·
VAS + QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for Carpal Tunnel Syndrome (CTS).

View Circle detail →
PRP
PRP
G56.03
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for Carpal Tunnel Syndrome (CTS).

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023 and is projected to reach about $1.2 billion by 2032.  Carpal Tunnel Syndrome is considered the most common entrapment neuropathy, accounting for 90% of entrapment neuropathy cases globally.  With modern jobs increasingly involving computer use and repetitive tasks, some reports suggest a rising prevalence of carpal tunnel syndrome.  As demand to treat CTS increases, manufacturers will seek real-world safety and efficacy data to enhance product development and regulatory approvals.

This Circle helps physicians obtain and aggregate high-quality real-world data from PRP treatments that companies are actively seeking.  Participation is minimally burdensome, and members will receive recurring license fees based on their contribution of treatment cases, outcomes, and other relevant data.

E66.0-96372
Private Circle

Longevity Medicine - GLP-1

General Conditions
 ·
Obesity and elongated lifespan
 ·
GLP-1; GAD-7

This Circle is the official repository for real-world data contributed, aggregated and utilized by the Longevity Docs community.

View Circle detail →
GLP-1 Intervention
GLP-1 Intervention
E66.0
96372

This Circle is the official repository for real-world data contributed, aggregated and utilized by the Longevity Docs community. These real-world results are the building blocks of real-world evidence, which are crucial to demonstrating safety and efficacy of our various longevity protocols, products and technologies. Be a member, and you can both access and contribute to this valuable data set, and we can all help advance the science, reputation and adoption of this emerging field.

M20.40-97026-P61
Physicians-Owned Circle

Foot and Ankle / Post-OP Proximal Interphalangeal (Hammer Toe) / Class IV Laser / VAS+FADI

Foot (Toe)
 ·
Post-OP Proximal Interphalangeal (Hammer Toe)
 ·
VAS, FADI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Proximal Interphalangeal (Hammer Toe) Post-Op recovery.

View Circle detail →
Class IV Laser
Class IV Laser
M20.41 / M20.42 / Z47.89
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Proximal Interphalangeal (Hammer Toe) Post-Op recovery.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Prevalence of hammer toe surgery increases with age. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing laser products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Proximal Interphalangeal (Hammer Toe) Post-Op recovery cases, outcomes and other case data.

Z47.89-97026-P60
Physicians-Owned Circle

Foot and Ankle / Post-OP / Class IV Laser / VAS+FADI

Foot, Ankle
 ·
Post-OP Bunionectomy
 ·
VAS, FADI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Post-Op recovery.

View Circle detail →
Class IV Laser
Class IV Laser
M21.9 / M20.10 / M20.11 / M20.12 / M72.2
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Post-Op recovery.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. The prevalence of Bunions is approximately 19% of people globally. The prevalences of both bunionectomies and hammer toe surgeries increase with age. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing laser products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Post-Op recovery cases, outcomes and other case data.

N52.9-0101T-P59
Physicians-Owned Circle

Male Reproductive System / Erectile Dysfunction / Shockwave / IIEF-5+EQ-5D-L

Male Reproductive System
 ·
Erectile Dysfunction
 ·
IIEF-5, EQ-5D-L

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Erectile Dysfunction (ED).

View Circle detail →
Shockwave
Shockwave
N52.01 / N52.02 / N52.1 / N52.3 / F52.8
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Erectile Dysfunction (ED).

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. There is an increasing interest in men's sexual health and well being. With this increasing attention, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. That spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Erectile Dysfunction (ED) cases, outcomes and other case data.

N80.9-0101T-P58
Physicians-Owned Circle

Female Reproductive System / Endometriosis / Shockwave / PROMIS

Female Reproductive System
 ·
Endometriosis
 ·
PROMIS

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Endometriosis.

View Circle detail →
Shockwave
Shockwave
N80.0 / N80.1 / N80.2 / N80.3 / N80.4
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Endometriosis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. There is an increasing interest in women's sexual health and well being. With this increasing attention, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. That spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Endometriosis cases, outcomes and other case data.

E28.2-0101T-P57
Physicians-Owned Circle

Female Reproductive System / Polycystic Ovarian Syndrome (PCOS) / Shockwave / PROMIS

Female Reproductive System
 ·
Polycystic Ovarian Syndrome
 ·
PROMIS

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Polycystic Ovarian Syndrome (PCOS).

View Circle detail →
Shockwave
Shockwave
E28.2 / N97.0 / N91.2
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Polycystic Ovarian Syndrome (PCOS).

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. There is an increasing interest in women's sexual health and well being. With this increasing attention, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. That spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of PCOS cases, outcomes and other case data.

M76.80-0101T-P35
Physicians-Owned Circle

Tibia / Medial Tibial Stress Syndrome / Shockwave / VAS+LEFS

Tibia
 ·
Medial Tibial Stress Syndrome
 ·
VAS, LEFS

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Medial Tibial Stress Syndrome.

View Circle detail →
Shockwave
Shockwave
M76.81 / M76.82 / M76.89 / M77.8 / M76.50 / M76.7
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Medial Tibial Stress Syndrome.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Medial Tibial Stress Syndrome (MTSS), commonly known as Shin Splints, is one of the most common injuries in runners and athletes involved in high-impact sports. It's estimated that up to 16% of runners may experience MTSS at some point in their athletic careers. MTSS is seen more commonly in younger athletes, particularly in those aged 18-25, although it can affect individuals of all ages who engage in repetitive weight-bearing activities. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Medial Tibial Stress Syndrome cases, outcomes and other case data.

M76.8-0232T-P15
Physicians-Owned Circle

Gluteal Region / Gluteal Tendinopathy / PRP+HA / VAS+VISA-G

Gluteal Region
 ·
Gluteal Tendinopathy
 ·
VAS, VISA-G

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and/or Hyaluronic Acid (HA) for Gluteal Tendinopathy.

View Circle detail →
PRP, Hyaluronic Acid
PRP, Hyaluronic Acid
M76.50 / M76.51 / M76.52 / M75.0 / M75.1 / M75.2
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and/or Hyaluronic Acid (HA) for Gluteal Tendinopathy.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. Gluteal Tendinopathy affects women more frequently but the prevalence of this indication increases with age across both women and men. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Gluteal Tendinopathy. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of PRP and/or HA cases, outcomes and other case data.

M62.89-0101T-P39
Physicians-Owned Circle

Pelvis / Pelvic Floor Dysfunction / Shockwave / PROMIS+PUF+ICIQ-UI

Pelvis
 ·
Pelvic Floor Dysfunction
 ·
PROMIS, PUF, ICIQ-UI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Pelvic Floor Dysfunction The.

View Circle detail →
Shockwave
Shockwave
M62.81 / M62.9 / M62.831 / M62.838 / M60.9 / M79.1
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Pelvic Floor Dysfunction

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. The prevalence of pelvic floor dysfunction in women is high. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Pelvic Floor Dysfunction cases, outcomes and other case data.

M17.9-0330T-P53
Physicians-Owned Circle

Knee / Osteoarthritis / Injectable Hydrogels / VAS+KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS, KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Injectable Hydrogels for Knee Osteoarthritis.

View Circle detail →
Injectable Hydrogels
Injectable Hydrogels
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
0330T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Injectable Hydrogels for Knee Osteoarthritis.

The Hydrogel Market was valued at $23.4 Billion in 2023, and is estimated to grow to $45.7 Billion by 2033. Knee Osteoarthritis affects approximately 10% of men and 18% of women aged 60 and older globally. In individuals over 65, the prevalence may rise to as high as 40-50%. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing hydrogel products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M16.9-97026-P52
Physicians-Owned Circle

Hip / Osteoarthritis / Class IV Laser / VAS+HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS, HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Hip Osteoarthritis.

View Circle detail →
Class IV Laser
Class IV Laser
M16.0 / M16.10 / M16.11 / M16.12 / M16.7 / M17.9
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Hip Osteoarthritis.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. In terms of prevalence, hip osteoarthritis is the third most common of adult men and women. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip Osteoarthritis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M54.5-97026-P50
Physicians-Owned Circle

Lumbar Region / Low-Back Pain / Class IV Laser / VAS+ODI

Lumbar Region (Low-Back)
 ·
Low-Back Pain
 ·
VAS, ODI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Low Back Pain.

View Circle detail →
Class IV Laser
Class IV Laser
M54.4 / M54.6 / M54.7 / M54.8 / M54.9 / M53.2
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Low Back Pain.  

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Around 60% to 80% of people will experience Low Back Pain at some point in their lives. Low Back Pain is more common in adults aged 30 to 50, with the prevalence rising in older age groups due to degenerative changes in the spine. Low Back Pain of adult men and women is treated area for Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Low Back Pain. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Low Back Pain cases, outcomes and other case data.

M76.6-97026-P49
Physicians-Owned Circle

Foot and Ankle / Achilles Tendon Disorders / Class IV Laser / VAS+VISA-A

Achilles
 ·
Achilles Tendon Disorders
 ·
VAS, VISA-A

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Achilles Tendon Disorders.

View Circle detail →
Class IV Laser
Class IV Laser
M76.50 / M76.51 / M76.52 / M77.9 / M75.81 / M77.0
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Achilles Tendon Disorders.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Achilles Tendon Disorders are among the most common types of tendinopathies. Achilles Tendon Disorders are fairly common in the general population, affecting around 1-2% of individuals overall. The prevalence is significantly higher in athletes, especially those who participate in high-impact sports. For individuals over the age of 40, Achilles Tendon Disorders are more prevalent due to degenerative changes. Achilles Tendon Disorders of adult men and women is treated area for Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Achilles Tendon Disorders. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Achilles Tendon Disorders cases, outcomes and other case data.

M54.2-97026-P48
Physicians-Owned Circle

Cervical Region / Neck Pain / Class IV Laser / VAS+NDI

Cervical Region
 ·
Neck Pain
 ·
VAS, NDI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Neck Pain.

View Circle detail →
Class IV Laser
Class IV Laser
M54.0 / M54.5 / M53.0 / M53.1 / M50.30 / M50.20
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Neck Pain.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Neck Pain is among the top 10 causes of disability worldwide. Neck Pain affects 15% to 20% of adults at any given time, making it one of the most frequent musculoskeletal complaints. The prevalence of Neck Pain tends to increase with age, with the highest rates found in individuals aged 30 to 50 years. However, Neck Pain can also affect younger people, especially those who engage in sedentary activities. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Neck Pain. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Neck Pain cases, outcomes and other case data.

M17.9-97026-P47
Physicians-Owned Circle

Knee / Osteoarthritis / Class IV Laser / VAS+KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS, KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Knee Osteoarthritis.

View Circle detail →
Class IV Laser
Class IV Laser
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Knee Osteoarthritis.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Knee Osteoarthritis affects approximately 10% of men and 18% of women aged 60 and older globally. In individuals over 65, the prevalence may rise to as high as 40-50%. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing laser products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M72.2-97026-P45
Physicians-Owned Circle

Foot and Ankle / Plantar Fasciitis / Class IV Laser / VAS+FFI

Foot, Ankle
 ·
Plantar Fasciitis
 ·
VAS, FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Plantar Fasciitis.

View Circle detail →
Class IV Laser
Class IV Laser
M72.0 / M72.1 / M72.9 / M79.1 / M79.7 / M77.9
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Plantar Fasciitis.  

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. The prevalence of Plantar Fasciitis is around 10% of the population, with peak incidence in people aged 40 to 60. Plantar Fasciitis of adult men and women is treated area for Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Plantar Fasciitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Plantar Fasciitis cases, outcomes and other case data.

M76.50-97026-P44
Physicians-Owned Circle

Knee / Patellar Tendinitis / Class IV Laser / VAS+VISA-P

Knee
 ·
Patellar Tendinitis
 ·
VAS, VISA-P

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Patellar Tendinitis.

View Circle detail →
Class IV Laser
Class IV Laser
M76.51 / M76.52 / M77.9 / M75.81 / M77.0 / M75.2
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Patellar Tendinitis.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. It is estimated that 14–20% of athletes in certain sports (basketball, volleyball, and running) may experience Patellar Tendinitis at some point in their careers. Also, Patellar Tendinitis can affect non-athletes, especially middle-aged individuals who engage in recreational sports or activities that involve repetitive knee movements. Patellar Tendinitis of adult men and women is treated area for Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Patellar Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Patellar Tendinitis cases, outcomes and other case data.

M17.9-0101T-P42
Physicians-Owned Circle

Bilateral Knees / Osteoarthritis / EMTT+Shockwave+Injectable Hydrogel / VAS+KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS, KOOS JR

This Circle unites providers from around in the world in the evidence-based standardization of Effectiveness and Safety of EMTT, Shockwave, and/or.

View Circle detail →
EMTT, Shockwave, Injectable Hydrogel
EMTT, Shockwave, Injectable Hydrogel
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
0101T

This Circle unites providers from around in the world in the evidence-based standardization of Effectiveness and Safety of EMTT, Shockwave, and/or Hydrogel Treatments in Knee OA. Each Circle member will deploy this shared protocol to begin enrolling, monitoring, and obtaining action real-world data from their relevant clinical cases. The Circle further allows members to aggregate, analyze and benchmark their de-identified data, helping to derive clinical evidence and to inform their clinical decision-making.

M17.9-0101T-P41
Physicians-Owned Circle

Knee / Osteoarthritis / EMTT+Shockwave+Injectable Hydrogel / VAS+KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS, KOOS JR

This Circle unites providers from around in the world in the evidence-based standardization of Effectiveness and Safety of EMTT, Shockwave, and/or.

View Circle detail →
EMTT, Shockwave, Injectable Hydrogel
EMTT, Shockwave, Injectable Hydrogel
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
0101T

This Circle unites providers from around in the world in the evidence-based standardization of Effectiveness and Safety of EMTT, Shockwave, and/or Hydrogel Treatments in Knee OA. Each Circle member will deploy this shared protocol to begin enrolling, monitoring, and obtaining action real-world data from their relevant clinical cases. The Circle further allows members to aggregate, analyze and benchmark their de-identified data, helping to derive clinical evidence and to inform their clinical decision-making.

F52.3-0101T-P40
Physicians-Owned Circle

Female Reproductive System / Clitoral Enhancement / Shockwave / FSFI

Female Reproductive System
 ·
Clitoral Enhancement
 ·
FSFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Clitoral Enhancement.

View Circle detail →
Shockwave
Shockwave
F52.0 / F52.1 / F52.2 / F52.4 / F52.5 / F52.8
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Clitoral Enhancement.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. There is an increasing interest in women's sexual health and well being. With this increasing attention, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. That spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Clitoral Enhancement cases, outcomes and other case data.

M19.079-0101T-P38
Physicians-Owned Circle

Foot and Ankle / Osteoarthritis / Shockwave / VAS+FFI

Foot, Ankle
 ·
Osteoarthritis
 ·
VAS, FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Foot Osteoarthritis.

View Circle detail →
Shockwave
Shockwave
M19.071 / M19.072 / M19.00 / M19.90 / M19.91 / M19.92
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Foot Osteoarthritis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. The prevalence of Foot Osteoarthritis is approximately 20-30% of people aged 50 and older. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Foot Osteoarthritis cases, outcomes and other case data.

M72.2-0101T-P37
Physicians-Owned Circle

Foot and Ankle / Plantar Fasciitis / Shockwave / VAS+FFI

Foot, Ankle
 ·
Plantar Fasciitis
 ·
VAS, FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Plantar Fasciitis.

View Circle detail →
Shockwave
Shockwave
M72.0 / M72.1 / M72.9 / M79.1 / M79.7 / M77.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Plantar Fasciitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. The prevalence of Plantar Fasciitis is around 10% of the population, with peak incidence in people aged 40 to 60. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Plantar Fasciitis cases, outcomes and other case data.

M76.6-0101T-P36
Physicians-Owned Circle

Foot and Ankle / Achilles Tendon Disorders / Shockwave / VAS+VISA-A

Achilles
 ·
Achilles Tendon Disorders
 ·
VAS, VISA-A

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Achilles Tendon Disorders.

View Circle detail →
Shockwave
Shockwave
M76.50 / M76.51 / M76.52 / M77.9 / M75.81 / M77.0
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Achilles Tendon Disorders.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Achilles Tendon Disorders are among the most common types of tendinopathies. Achilles Tendon Disorders are fairly common in the general population, affecting around 1-2% of individuals overall. The prevalence is significantly higher in athletes, especially those who participate in high-impact sports. For individuals over the age of 40, Achilles Tendon Disorders are more prevalent due to degenerative changes. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Achilles Tendon Disorders. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Achilles Tendon Disorders cases, outcomes and other case data.

M77.8-0101T-P34
Physicians-Owned Circle

Knee / Knee Calcific Tendinitis / Shockwave / VAS+KOOS JR

Knee
 ·
Calcific Tendinitis
 ·
VAS, KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Knee Calcific Tendinitis.

View Circle detail →
Shockwave
Shockwave
M77.0 / M77.1 / M77.10 / M76.89 / M76.50 / M76.7
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Knee Calcific Tendinitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Knee Calcific Tendinitis tends to occur more frequently in middle-aged adults, typically between the ages of 40 and 60, though it can affect individuals of any age. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Calcific Tendinitis cases, outcomes and other case data.

M76.50-0101T-P33
Physicians-Owned Circle

Knee / Patellar Tendinitis / Shockwave / VAS+VISA-P

Knee
 ·
Patellar Tendinitis
 ·
VAS, VISA-P

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Patellar Tendinitis.

View Circle detail →
Shockwave
Shockwave
M76.51 / M76.52 / M77.9 / M75.81 / M77.0 / M75.2
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Patellar Tendinitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. It is estimated that 14–20% of athletes in certain sports (basketball, volleyball, and running) may experience Patellar Tendinitis at some point in their careers. Also, Patellar Tendinitis can affect non-athletes, especially middle-aged individuals who engage in recreational sports or activities that involve repetitive knee movements. Patellar Tendinitis of adult men and women is treated area for shockwave therapy. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Patellar Tendinitis cases, outcomes and other case data.

M17.9-0101T-P32
Physicians-Owned Circle

Knee / Osteoarthritis / Shockwave / VAS+KOOS JR

Knee
 ·
Osteoarthritis
 ·
VAS, KOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Knee Osteoarthritis.

View Circle detail →
Shockwave
Shockwave
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Knee Osteoarthritis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Knee Osteoarthritis affects approximately 10% of men and 18% of women aged 60 and older globally. In individuals over 65, the prevalence may rise to as high as 40-50%. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Knee Osteoarthritis cases, outcomes and other case data.

M54.5-0101T-P21
Physicians-Owned Circle

Lumbar Region / Low-Back Pain / Shockwave / VAS+ODI

Lumbar Region (Low-Back)
 ·
Low-Back Pain
 ·
VAS, ODI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Low Back Pain.

View Circle detail →
Shockwave
Shockwave
M54.4 / M54.6 / M54.7 / M54.8 / M54.9 / M53.2
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Low Back Pain.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Around 60% to 80% of people will experience Low Back Pain at some point in their lives. Low Back Pain is more common in adults aged 30 to 50, with the prevalence rising in older age groups due to degenerative changes in the spine. Low Back Pain is one of the leading causes of disability worldwide, and it results in a significant economic burden. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Low Back Pain cases, outcomes and other case data.

M76.8-0232T-P18
Physicians-Owned Circle

Posterior Femoral Region / Hamstring Tendinopathy / PRP+HA / VAS+VISA-H

Hamstrings
 ·
Hamstring Tendinopathy
 ·
VAS, VISA-H

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid for Hamstring Tendinopathy.

View Circle detail →
PRP + Hyaluronic Acid
PRP + Hyaluronic Acid
M76.50 / M76.51 / M76.52 / M75.0 / M75.1 / M75.2
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid for Hamstring Tendinopathy.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. Hamstring Tendinopathy is a common indication among athletes and active adults, though it affects everyone. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hamstring Tendinopathy. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hamstring Tendinopathy cases, outcomes and other case data.

M54.2-0101T-P20
Physicians-Owned Circle

Cervical Region / Neck-Pain / Shockwave / VAS+NDI

Cervical Region
 ·
Neck Pain
 ·
VAS, NDI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Neck Pain.

View Circle detail →
Shockwave
Shockwave
M54.0 / M54.5 / M53.0 / M53.1 / M50.30 / M50.20
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Neck Pain.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Neck Pain is among the top 10 causes of disability worldwide. Neck Pain affects 15% to 20% of adults at any given time, making it one of the most frequent musculoskeletal complaints. The prevalence of Neck Pain tends to increase with age, with the highest rates found in individuals aged 30 to 50 years. However, Neck Pain can also affect younger people, especially those who engage in sedentary activities. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Neck Pain cases, outcomes and other case data.

M76.6-0232T-P19
Physicians-Owned Circle

Foot and Ankle / Achilles Tendon Disorders / PRP+HA / VAS+VISA-A

Achilles
 ·
Achilles Tendon Disorders
 ·
VAS, VISA-A

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid (HA) for Achilles Tendinitis.

View Circle detail →
PRP
PRP
M76.50 / M76.51 / M76.52 / M77.9 / M75.81 / M77.0
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid (HA) for Achilles Tendinitis.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Achilles Tendon Disorders are among the most common types of tendinopathies. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. Achilles Tendon Disorders are fairly common in the general population, affecting around 1-2% of individuals overall. The prevalence is significantly higher in athletes, especially those who participate in high-impact sports. For individuals over the age of 40, Achilles Tendon Disorders are more prevalent due to degenerative changes. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Achilles Tendon Disorders. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Achilles Tendinitis cases, outcomes and other case data.

N95.1-0232T-P13
Physicians-Owned Circle

Endocrine System / Perimenopause / PRP / Cervantes-SF - US

Endocrine System
 ·
Perimenopause
 ·
Cervantes-SF - US

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for perimenopausal women.

View Circle detail →
PRP
PRP
N95.0 / N95.2 / N95.3 / E28.9 / M81.0 / M79.7
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for perimenopausal women.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023 and is projected to reach about $1.2 billion by 2032. Perimenopause presents a unique opportunity for PRP therapies, addressing a variety of health and wellness concerns specific to this demographic, such as skin rejuvenation, hair restoration, and improving vaginal health. As demand grows, manufacturers will increasingly seek real-world safety and efficacy data to enhance product development and regulatory approvals.

This Circle helps physicians obtain and aggregate high-quality real-world data from perimenopausal treatments that companies are actively seeking. Participation is minimally burdensome, and members will receive recurring license fees based on their contribution of treatment cases, outcomes, and other relevant data.

N95.1-0232T-P14
Physicians-Owned Circle

Endocrine System / Perimenopause / PRP / Greene Climacteric Scale - EU

Endocrine System
 ·
Perimenopause
 ·
Greene Climacteric Scale - EU

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for perimenopausal women.

View Circle detail →
PRP
PRP
N95.0 / N95.2 / N95.3 / E28.9 / M81.0 / M79.7
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for perimenopausal women.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023 and is projected to reach about $1.2 billion by 2032. Perimenopause presents a unique opportunity for PRP therapies, addressing a variety of health and wellness concerns specific to this demographic, such as skin rejuvenation, hair restoration, and improving vaginal health. As demand grows, manufacturers will increasingly seek real-world safety and efficacy data to enhance product development and regulatory approvals.

This Circle helps physicians obtain and aggregate high-quality real-world data from perimenopausal treatments that companies are actively seeking. Participation is minimally burdensome, and members will receive recurring license fees based on their contribution of treatment cases, outcomes, and other relevant data.

M72.2-0232T-P12
Physicians-Owned Circle

Foot and Ankle / Plantar Fasciitis / PRP / VAS+FFI

Foot, Ankle
 ·
Plantar Fasciitis
 ·
VAS, FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Plantar Fasciitis.

View Circle detail →
PRP
PRP
M72.0 / M72.1 / M72.9 / M79.1 / M79.7 / M77.9
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Plantar Fasciitis.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The prevalence of Plantar Fasciitis is around 10% of the population, with peak incidence in people aged 40 to 60. Plantar Fasciitis of adult men and women is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Plantar Fasciitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Plantar Fasciitis cases, outcomes and other case data.

M76.6-0232T-P11
Physicians-Owned Circle

Foot and Ankle / Achilles Tendon Disorders / PRP / VAS+VISA-A

Achilles
 ·
Achilles Tendon Disorders
 ·
VAS, VISA-A

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Achilles Tendinitis.

View Circle detail →
PRP
PRP
M76.50 / M76.51 / M76.52 / M77.9 / M75.81 / M77.0
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Achilles Tendinitis.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Achilles Tendon Disorders are among the most common types of tendinopathies. Achilles Tendon Disorders are fairly common in the general population, affecting around 1-2% of individuals overall. The prevalence is significantly higher in athletes, especially those who participate in high-impact sports. For individuals over the age of 40, Achilles Tendon Disorders are more prevalent due to degenerative changes. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Achilles Tendon Disorders. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Achilles Tendinitis cases, outcomes and other case data.

M54.5-0232T-P2
Physicians-Owned Circle

Lumbar Region / Low-Back Pain / PRP / VAS+ODI

Lumbar Region (Low-Back)
 ·
Low-Back Pain
 ·
VAS, ODI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Low Back Pain.

View Circle detail →
PRP
PRP
M54.4 / M54.6 / M54.3 / M47.812 / M51.26 / M51.36
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Low Back Pain.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Low Back Pain remains one of the most prevalent indications of adult men and women, and is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Low Back Pain. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Low Back Pain cases, outcomes and other case data.

M54.2-0232T-P1
Physicians-Owned Circle

Cervical Region / Neck Pain / PRP / VAS+NDI

Cervical Region
 ·
Neck Pain
 ·
VAS, NDI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Neck Pain.

View Circle detail →
PRP
PRP
M53.0 / M53.1 / M50.30 / M50.20 / M47.812 / M48.02
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Neck Pain.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Neck Pain is a highly prevalent indication of adult men and women, and is treated with PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Neck Pain. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Neck Pain cases, outcomes and other case data.

M76.50-0232T-P10
Physicians-Owned Circle

Knee / Patellar Tendinitis / PRP / VAS+VISA-P

Knee
 ·
Osteoarthritis
 ·
VAS, VISA-P

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Patellar Tendinitis.

View Circle detail →
PRP
PRP
M76.51 / M76.52 / M77.9 / M75.81 / M77.0 / M75.2
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Patellar Tendinitis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. It is estimated that 14–20% of athletes in certain sports (basketball, volleyball, and running) may experience Patellar Tendinitis at some point in their careers. Also, Patellar Tendinitis can affect non-athletes, especially middle-aged individuals who engage in recreational sports or activities that involve repetitive knee movements. Patellar Tendinitis of adult men and women is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Patellar Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Patellar Tendinitis cases, outcomes and other case data.

M76.89-0101T-P31
Physicians-Owned Circle

Hip / Hip Calcific Tendinitis / Shockwave / VAS+HOOS JR

Hip
 ·
Calcific Tendinitis
 ·
VAS, HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Hip Osteoarthritis.

View Circle detail →
Shockwave
Shockwave
M76.8 / M76.50 / M76.51 / M76.52 / M77.8 / M76.7
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Hip Osteoarthritis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. In terms of prevalence, hip osteoarthritis is the third most common of adult men and women. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M16.9-0101T-P30
Physicians-Owned Circle

Hip / Osteoarthritis / Shockwave / VAS+HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS, HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Hip Osteoarthritis.

View Circle detail →
Shockwave
Shockwave
M16.0 / M16.10 / M16.11 / M16.12 / M16.7 / M17.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Hip Osteoarthritis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. In terms of prevalence, hip osteoarthritis is the third most common of adult men and women. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M16.9-0232T-P8
Physicians-Owned Circle

Hip / Osteoarthritis / PRP / VAS+HOOS JR

Hip
 ·
Osteoarthritis
 ·
VAS, HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Hip Osteoarthritis.

View Circle detail →
PRP
PRP
M16.11 / M16.12 / M16.21 / M17.9 / M24.50 / M24.11
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Hip Osteoarthritis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. In terms of prevalence, hip osteoarthritis is the third most common of adult men and women globally, and is commonly treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip OA. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.

M77.1-97026-P51
Physicians-Owned Circle

Elbow / Lateral Epicondylitis / Class IV Laser / VAS+PREE

Elbow
 ·
Lateral Epicondylitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser therapy for Medial Epicondylitis.

View Circle detail →
Class IV Laser
Class IV Laser
M77.0 / M77.2 / M76.81 / M79.1 / M75.40 / M76.81
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser therapy for Medial Epicondylitis.

The Laser Therapy market was valued at $3.11 Billion in 2023, and is estimated to grow to over $5.5 Billion by 2032. Medial Epicondylitis is the most common condition affecting the elbow and have a global prevalence of 1% to 3%. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Medial Epicondylitis. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Medial Epicondylitis cases, outcomes and other case data.

M77.1-97026-P46
Physicians-Owned Circle

Elbow / Medial Epicondylitis / Class IV Laser / VAS+PREE

Elbow
 ·
Medial Epicondylitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser therapy for Medial Epicondylitis.

View Circle detail →
Class IV Laser
Class IV Laser
M77.0 / M77.10 / M77.11 / M77.12 / M77.8 / M77.9
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser therapy for Medial Epicondylitis.

The Laser Therapy market was valued at $3.11 Billion in 2023, and is estimated to grow to over $5.5 Billion by 2032. Medial Epicondylitis is the most common condition affecting the elbow and have a global prevalence of 1% to 3%. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Medial Epicondylitis. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Medial Epicondylitis cases, outcomes and other case data.

M77.8-0101T-P29
Physicians-Owned Circle

Elbow / Elbow Calcific Tendinitis / Shockwave / VAS+PREE

Elbow
 ·
Elbow Calcific Tendinitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Elbow Calcific Tendinitis.

View Circle detail →
Shockwave
Shockwave
M77.0 / M77.1 / M77.10 / M76.89 / M76.50 / M76.7
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Elbow Calcific Tendinitis.  

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Elbow Calcific Tendinitis of adult men and women is treated area for Shockwave therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Elbow Calcific Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Elbow Calcific Tendinitis cases, outcomes and other case data.

M77.1-0101T-P28
Physicians-Owned Circle

Elbow / Medial Epicondylitis / Shockwave / VAS+PREE

Elbow
 ·
Medial Epicondylitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Medial Epicondylitis.

View Circle detail →
Shockwave
Shockwave
M77.0 / M77.10 / M77.11 / M77.12 / M77.8 / M77.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Medial Epicondylitis.  

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Medial Epicondylitis is a common indication among adult men and women, ages 30 to 50. It is often treated with Shockwave. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Medial Epicondylitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Medial Epicondylitis cases, outcomes and other case data.

M77.1-0101T-P27
Physicians-Owned Circle

Elbow / Lateral Epicondylitis / Shockwave / VAS + PREE

Elbow
 ·
Lateral Epicondylitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Lateral Epicondylitis.

View Circle detail →
Shockwave
Shockwave
M77.0 / M77.10 / M77.11 / M77.12 / M77.8 / M77.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Lateral Epicondylitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Prevalence of Lateral Epicondylitis, commonly known as Tennis Elbow, in the general population is around 1-3%. It most commonly affects individuals between the ages of 30 and 50. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Lateral Epicondylitis cases, outcomes and other case data.

M77.1-0232T-P17
Physicians-Owned Circle

Elbow / Epicondylitis / PRP+HA / VAS+PRTEE

Elbow
 ·
Epicondylitis
 ·
VAS, PRTEE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid for Lateral Epicondylitis.

View Circle detail →
PRP + Hyaluronic Acid
PRP + Hyaluronic Acid
M77.0 / M77.2 / M76.81 / M79.1 / M75.40 / M76.81
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid for Lateral Epicondylitis.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. Lateral Epicondylitis is a common indication among adult men and women, ages 30 to 50. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Lateral Epicondylitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Lateral Epicondylitis cases, outcomes and other case data.

M75.80-97026-P43
Physicians-Owned Circle

Shoulder / Shoulder Pain / Class IV Laser / VAS+QuickDASH

Shoulder
 ·
Shoulder Pain
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Shoulder Pain.

View Circle detail →
Class IV Laser
Class IV Laser
M75.81 / M75.82 / M75.0 / M75.1 / M75.2 / M75.3
97026

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Laser for Shoulder Pain.

The Laser Therapy market is valued at 5.22 Billion in 2024, and is estimated to grow to over 11 billion by 2032. Around 5–10% of adults will experience Shoulder Pain at some point in their lifetime. It becomes more common with age, particularly in individuals over 40. Athletes or individuals who engage in repetitive overhead activities, like baseball players, swimmers, or weightlifters, are at a higher risk of developing Shoulder Pain. Shoulder Pain in adult men and women is treated with Laser Therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Pain. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Pain cases, outcomes and other case data.

M75.80-0101T-P26
Physicians-Owned Circle

Shoulder / Rotator Cuff Tendinitis / Shockwave / VAS+QuickDASH

Shoulder
 ·
Rotator Cuff Tendinitis
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Rotator Cuff Tendinitis.

View Circle detail →
Shockwave
Shockwave
M75.81 / M75.82 / M75.0 / M75.1 / M75.2 / M75.3
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Rotator Cuff Tendinitis.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Rotator Cuff Tendinitis is the most common diagnosed, accounting for 65%-70% of all shoulder pain presented in clinical settings. Rotator Cuff Tendinitis increases with age, due to the degeneration of tendons. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Rotator Cuff Tendinitis cases, outcomes and other case data.

M75.1-0101T-P25
Physicians-Owned Circle

Shoulder / Rotator Cuff Tear / Shockwave / VAS + QuickDASH

Shoulder
 ·
Rotator Cuff Tear
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Rotator Cuff Tear.

View Circle detail →
Shockwave
Shockwave
M75.40 / M75.2 / M76.81 / M77.9 / M73.9 / M75.41
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Rotator Cuff Tear.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Rotator Cuff Tear is the most common diagnosed, accounting for 65%-70% of all shoulder pain presented in clinical settings. Rotator Cuff Tear increases with age, due to the degeneration of tendons. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Rotator Cuff Tear cases, outcomes and other case data.

M75.40-0101T-P24
Physicians-Owned Circle

Shoulder / Impingement Syndrome / Shockwave / VAS + QuickDASH

Shoulder
 ·
Impingement Syndrome
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Impingement Syndrome.

View Circle detail →
Shockwave
Shockwave
M75.41 / M75.42 / M75.1 / M75.5 / M77.9 / M73.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Impingement Syndrome.  

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Shoulder Impingement Syndrome of adult men and women is treated area for Shockwave therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Impingement Syndrome. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Impingement Syndrome cases, outcomes and other case data.

M75.3-0101T-P23
Physicians-Owned Circle

Shoulder / Calcific Tendinitis / Shockwave / VAS+SANE+QuickDASH

Shoulder
 ·
Calcific Tendinitis
 ·
VAS, SANE, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Calcific Tendinitis.

View Circle detail →
Shockwave
Shockwave
M75.1 / M75.40 / M75.5 / M75.4 / M73.1 / M73.9
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Calcific Tendinitis.  

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Shoulder Calcific Tendinitis of adult men and women is treated area for Shockwave therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Calcific Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Calcific Tendinitis cases, outcomes and other case data.

M75.1-0232T-P16
Physicians-Owned Circle

Shoulder / Rotator Cuff Tendinopathy / PRP+HA / VAS+QuickDASH

Shoulder
 ·
Rotator Cuff Tendinopathy
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid (HA) for Rotator Cuff Tendinopathy.

View Circle detail →
PRP
PRP
M75.40 / M75.2 / M76.81 / M77.9 / M73.9 / M75.41
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP and Hyaluronic Acid (HA) for Rotator Cuff Tendinopathy.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The HA Market is currently estimated at 11.14 Billion (2025) and predicted to grow to about 19.94 Billion by 2034. The prevalence of Rotator Cuff Tendinopathy is around 5% to 10% among the general population. The condition becomes more prevalent with age, particularly in individuals over 40 years old. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Rotator Cuff Tendinopathy. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Rotator Cuff Tendinopathy cases, outcomes and other case data.

M75.3-0232T-P3
Physicians-Owned Circle

Shoulder / Calcific Tendinitis / PRP / VAS+SANE+QuickDASH

Shoulder
 ·
Calcific Tendinitis
 ·
VAS, SANE, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Calcific Tendinitis.

View Circle detail →
PRP
PRP
M75.1 / M75.40 / M75.5 / M75.4 / M73.1 / M73.9
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Calcific Tendinitis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Shoulder Calcific Tendinitis of adult men and women is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Calcific Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Calcific Tendinitis cases, outcomes and other case data.

M75.9-0101T-P22
Physicians-Owned Circle

Shoulder / Shoulder Tendinopathy / Shockwave / VAS+SANE+QuickDASH

Shoulder
 ·
Shoulder Tendinopathy
 ·
VAS, SANE, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Tendinopathy.

View Circle detail →
Shockwave
Shockwave
M75.0 / M75.1 / M75.2 / M75.3 / M75.4 / M75.8
0101T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Tendinopathy.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Shoulder Tendinopathy is the most common diagnosed, accounting for 65%-70% of all shoulder pain presented in clinical settings. Shoulder Tendinopathy increases with age, due to the degeneration of tendons. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Tendinopathy cases, outcomes and other case data.

M77.1-0232T-P7
Physicians-Owned Circle

Elbow / Lateral Epicondylitis / PRP / VAS + PREE

Elbow
 ·
Lateral Epicondylitis
 ·
VAS, PREE

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Lateral Epicondylitis.

View Circle detail →
PRP
PRP
M77.0 / M77.2 / M76.81 / M79.1 / M75.40 / M76.81
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Lateral Epicondylitis.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Lateral Epicondylitis is a common indication among adult men and women, ages 30 to 50. It is often treated with PRP. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Lateral Epicondylitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Lateral Epicondylitis cases, outcomes and other case data.

M75.40-0232T-P4
Physicians-Owned Circle

Shoulder / Impingement Syndrome / PRP / VAS + QuickDASH

Shoulder
 ·
Impingement Syndrome
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Impingement Syndrome.

View Circle detail →
PRP
PRP
M75.41 / M75.42 / M75.1 / M75.5 / M77.9 / M73.9
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Impingement Syndrome.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. Shoulder Impingement Syndrome of adult men and women is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Impingement Syndrome. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Impingement Syndrome cases, outcomes and other case data.

M75.1-0232T-P5
Physicians-Owned Circle

Shoulder / Rotator Cuff Tear / PRP / VAS + QuickDASH

Shoulder
 ·
Rotator Cuff Tear
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Rotator Cuff Tear.

View Circle detail →
PRP
PRP
M75.40 / M75.2 / M76.81 / M77.9 / M73.9 / M75.41
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Shoulder Rotator Cuff Tear.  

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The global prevalence of rotator cuff tears is between 10% and 20%, and is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Shoulder Rotator Cuff Tears. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Rotator Cuff Tear cases, outcomes and other case data.

M75.1-0232T-P6
Physicians-Owned Circle

Shoulder / Rotator Cuff Tendinitis / PRP / VAS + QuickDASH

Shoulder
 ·
Rotator Cuff Tendinitis
 ·
VAS, QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Rotator Cuff Tendinitis.

View Circle detail →
PRP
PRP
M75.40 / M75.2 / M76.81 / M77.9 / M73.9 / M75.41
0232T

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Rotator Cuff Tendinitis.

The Platelet Rich Plasma “PRP” Market was valued at about $480 million in 2023, and is projected to reach about $1.2 billion by 2032. The prevalence of Rotator Cuff Tendinitis is 2% to 8%, with prevalence increasing with age. Rotator Cuff Tendinitis is often treated with PRP. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Rotator Cuff Tendinitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Rotator Cuff Tendinitis cases, outcomes and other case data.

E29.1-96372-P56
Physicians-Owned Circle

Endocrine System / Low-T / BHRT / IIEF-5+AMS

Endocrine System
 ·
Low-T
 ·
IIEF-5 and AMS

This Circle helps physicians capture and monetize real-world data from their everyday delivery of BHRT for Low-testosterone.

View Circle detail →
Bioidentical Hormone Replacement Therapy
Bioidentical Hormone Replacement Therapy
E23.0 / E89.5 / Q55.4 / R53.8 / R68.8
96372

This Circle helps physicians capture and monetize real-world data from their everyday delivery of BHRT for Low-testosterone.

The Hormone Replacement Treatment Market is estimated to be over $40 billion in 2032. The global prevalence of low testosterone (low-T) in men is estimated to be anywhere between 10% and 40%. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for low-T. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of low-T cases, outcomes and other case data.

M16.9-27130-P55
Physicians-Owned Circle

Hip / Total Hip Arthroplasty / VAS + HOOS JR + VR-12

Hip
 ·
Any
 ·
VAS, HOOS JR, VR-12

The CMS Hospital Inpatient Quality Reporting Program (IQR) recently included performance measures for elective total hip arthroplasty procedures.

View Circle detail →
Total Arthroplasty
Total Arthroplasty
M16.0 / M16.11 / M16.12 / M16.7 / M17.9
27130

The CMS Hospital Inpatient Quality Reporting Program (IQR) recently included performance measures for elective total hip arthroplasty procedures.  Under CMS guidelines, hospitals must collect and submit data on more than 50 percent of eligible patients to maximize reimbursements.  This Circle streamlines patient and clinician data collection to evaluate improvements in quality of life by reducing pain and improving function for patients undergoing total hip arthroplasty procedures.  The aggregated dataset will allow physicians to evaluate certain quantitative benchmarks under the IQR for reimbursement.

M17.9-27447-P54
Physicians-Owned Circle

Knee / Total Knee Arthroplasty / VAS + KOOS JR + VR-12

Knee
 ·
Any
 ·
VAS, KOOS JR, VR-12

The CMS Hospital Inpatient Quality Reporting Program (IQR) recently included performance measures for elective total hip arthroplasty procedures.

View Circle detail →
Total Arthroplasty
Total Arthroplasty
M17.0 / M17.11 / M17.12 / M25.561 / M25.562
27445 / 27447

The CMS Hospital Inpatient Quality Reporting Program (IQR) recently included performance measures for elective total hip arthroplasty procedures.  Under CMS guidelines, hospitals must collect and submit data on more than 50 percent of eligible patients to maximize reimbursements.  This Circle streamlines patient and clinician data collection to assess improvements in quality of life by reducing pain and improving function for patients undergoing total hip arthroplasty procedures.  Remote collection of patient-reported pain and function statuses occurs routinely for up to 12 months following the procedure.

M17.9-0232T-P9
Physicians-Owned Circle

Knee / Osteoarthritis / PRP / KOOS Jr + VAS

Knee
 ·
Osteoarthritis
 ·
KOOS, Jr.; VAS

The PRP market was valued at about $480 million in 2023, projected to reach about $1.2 billion by 2032. Knee OA is one of the most common pathologies treated with PRP.

View Circle detail →
PRP
PRP
M17.0 / M17.11 / M17.12 / M23.81 / M25.561 / M25.562
0232T

The PRP market was valued at about $480 million in 2023, projected to reach about $1.2 billion by 2032.  Knee OA is one of the most common pathologies treated with PRP, either as a primary or adjunct therapy.

Platelet concentration, dosage, injection site, number of injections, and leukocyte count are among the treatment factors which should be correlated against standardized outcomes.  Informed patient consents, product(s) used, and adherence to Directions For Use are also key elements of establishing GCP datasets.  These are covered in this POC.

Each POC has a single Principal Investigator and a minimum of ten investigators.  They collaborate closely on the generation of a high-quality, validated and proprietary dataset with statistical and clinical significance.  That dataset, singly or in conjunction with other POC datasets, represent sustained value to product manufacturers, payers, researchers, and AI healthcare models.

Contributing physicians earn 85% of resulting POC license fees proportionate to their data contributions.  All POCs are based on RegenMed’s patented systems and processes, and do not interrupt clinical flow.  For more information on POCs, see here.

Not in the library

Request a new Circle.

Any clinician, society, sponsor, payer, public program or patient advocacy group can propose one. Send the clinical question, the population and the outcome measures you need, and our clinical team drafts the protocol with you, in any therapeutic area.

01
You state the question, the population and where the episode starts and ends
02
We research the key clinical questions, with AI assistance, and draft the protocol; your clinical leads finalize every question
03
The protocol is locked before the first patient enrolls, and the Circle opens with a Circle Code and its founding members

Access to a Circle is arranged with our team, not self-serve.

Membership, consent and dataset ownership follow the Circles Dataset Ownership Agreement, with terms set for each Circle. Tell us which one interests you and we will take it from there.

Request access
CIRCLE-CODE

Circle name

Region · Pathology · Treatment
×